US Povidone Prices Rise 1.93% Amid Higher Shipping Costs

Manufacturers face increased procurement costs for tablet binders as import economics tighten.

Updated on Oct. 21, 2026 in Inflation

Isometric editorial illustration of stacked industrial chemical drums in a warehouse, representing the supply chain and manufacturing procurement costs. — Povidone prices rose by 1.93% in September 2026, as pharmaceutical manufacturers faced increased procurement costs due to shifts in international shipping economics. AI Illustration. Upload story photo >

Live Poll

Do you expect the cost of your medications or supplements to rise soon?

Povidone prices in the United States rose by 1.93% in September 2026, driven by higher international shipping costs. Pharmaceutical manufacturers and other industrial buyers have responded by securing excipients for fourth-quarter production requirements.

Why it matters

The price adjustment reflects broader supply chain pressures as import economics shifted in September, directly impacting procurement costs for manufacturers of tablets, personal-care products, and dietary supplements.

Povidone prices rose by 1.93% in September 2026 compared to the prior month. This uptick, anchored by Povidone K-30 benchmarks in Houston, follows increased international shipping costs and robust procurement demand for excipients used in pharmaceutical manufacturing.

The details

Suppliers implemented the price hikes to shield margins from increased landed costs related to international shipping. To maintain operational continuity, pharmaceutical buyers accelerated procurement activity during September to ensure a stable supply of Povidone K-30 binders for their fourth-quarter production cycles.

September 2026: US povidone prices increased by 1.93 percent.
Q4 2026: Period for which pharmaceutical buyers secured excipients.
October-December 2026: Potential market softening period as new inventory arrives.
Early 2027: Expected gradual market recovery period.

Market Landscape

This povidone price adjustment follows the pattern of volatility in import economics established by rising international shipping costs as tracked by global container freight indices. It highlights the sensitivity of pharmaceutical excipient supply chains to sudden fluctuations in logistics expenses.

Manufacturers of tablets, supplements, and sanitizers should anticipate potential market softening during the fourth quarter as new inventory reaches the country. Procurement teams should monitor supplier pricing closely in early 2027 to capitalize on the expected gradual market recovery.

The takeaway

The recent price hike underscores the importance of securing essential excipients well in advance during periods of logistical instability. Operators should evaluate their current inventory levels and contract terms for binders to mitigate the risk of mid-quarter budget overruns.